Navigation Links
Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award

PARSIPPANY, N.J., Jan. 28 /PRNewswire/ -- Ferring Pharmaceuticals Inc. has announced that its hyaluronic acid therapy, EUFLEXXA(TM) (1% sodium hyaluronate) will serve as the title sponsor of the EUFLEXXA National Senior Games Hockey Championships and the EUFLEXXA GeezerJock of the Year Award.

"This is such a tremendous opportunity for both our brand and for senior athletes," said Alex Drigan, Product Manager, EUFLEXXA(TM). "We support all that the National Senior Games Association (NSGA) and Masters Athlete magazine do to promote healthy, active aging and hope that these sponsorships will help more seniors realize their athletic dreams."

"We are thrilled that EUFLEXXA(TM) is helping us ensure that more senior athletes will be able to compete in the sports that they love on the national level," said Phil Godfrey, President and Chief Executive Officer of NSGA. "Ferring is a loyal supporter of the NSGA's efforts and we truly appreciate how much this sponsorship does for advancing these efforts."

The EUFLEXXA(TM) GeezerJock of the Year Award is the premier award program presented by Masters Athlete magazine. The program recognizes excellence in Masters athletics. In addition to a single overall winner, the program also recognizes male and female winners in five age categories and a GeezerJock Executive of the Year award, recognizing the association head who has done the most to advance Masters athletics.

"We are excited that EUFLEXXA(TM) is sponsoring the GeezerJock of the Year Award," said Brian Reilly, publisher of Masters Athlete magazine. "Together with their sponsorships of major senior sporting events, it's clear that EUFLEXXA(TM) is deeply committed to improving the quality of life for Masters athletes."


EUFLEXXA(TM) (1% sodium hyaluronate) is the first and only non-avian derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). In a prospective, randomized, double-blind, head-to-head study versus the market leading HA therapy, significantly more patients were "pain-free" and "symptom- free" with EUFLEXXA(TM).(1)

The process used to manufacture EUFLEXXA(TM) produces the HA that most closely resembles the HA in healthy human synovial fluid and the most highly purified HA product available today. In addition, since it is not derived from an avian source (chicken or rooster combs), the risk of reactions related to avian proteins is eliminated.(2-7)

EUFLEXXA(TM) received PMA approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit

About the National Senior Games Association

A not-for-profit member of the United States Olympic Committee, the National Senior Games Association is dedicated to motivating senior men and women to lead a healthy lifestyle through the senior games movement. The NSGA governs the Summer National Senior Games, the largest multi-sport event in the world for seniors, and other national senior athletic events.

Serving as an umbrella for member state organizations across the United States that host State Senior Games, the NSGA supports and sanctions these member state organizations so that adults can participate in their state in events year-round, helping keep them motivated to achieve greater value and quality in their lives by staying healthy, active and fit.

The NSGA also works with state and federal agencies, colleges and universities to better understand and support healthy aging initiatives for seniors and partners with national leaders committed to senior health, wellness and quality of life. The NSGA is committed to providing information to support education and research initiatives enabling senior athletes and others to be better informed about ways to ensure healthy aging. For more information, please visit

About Masters Athlete

Masters Athlete, owned by Turnstile Publishing Company, boasts a circulation of 50,000 Masters athletes and is the only national publication covering the growing world of Masters sports, which are competitive athletic events for people 30-and-over. Since the magazine's launch in 2004 it has grown in both circulation and advertising revenues. Under the Turnstile umbrella of magazines, Masters Athlete is continuing to expand its reach among active baby boomers and other adult athletes.

The public can submit athletes for consideration as nominees for the EUFLEXXA GeezerJock of the Year Award via the online form at In each issue of the magazine throughout the year, the athletes selected as nominees will be profiled. The winners are determined by online voters and the Masters Athlete editorial board. In 2007, more than 6,000 online votes were cast. The winners were announced in the January/February 2008 issue.

1 Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006; 14:154-162.

2 Schiavinato A, Finesso M, Cortivo R, & Abatangelo G (2002). Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp Rheumatol 20, 445-454.

3 Goomer RS, Leslie K, Maris T, & Amiel D (2005). Native hyaluronan produces less hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res 239-245.

4 Leopold SS, Warme WJ, Pettis PD, & Shott S (2002). Increased frequency of acute local reaction to intra-articular hylan GF-20 (synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg Am 84-A, 1619- 1623.

5 Puttick MP, Wade JP, Chalmers A, Connell DG, & Rangno KK (1995). Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 22, 1311-1314.

6 Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, & Schumacher HR (2002). Are there distinctive inflammatory flares after hylan g-f 20 intraarticular injections? J Rheumatol 29, 2611-2614.

7 Chen AL, Desai P, Adler EM, & Di Cesare PE (2002). Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am 84-A, 1142-1147.

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Smart Medical Technology, Inc. Awarded Novation Contract for Ground-breaking Liftaem(TM) System that Aids Lifting and Transferring Patients
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
(Date:10/11/2017)... Charlotte, N.C. (PRWEB) , ... October 11, 2017 ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the ... Laboratories ( ASTER Labs ), Inc. has been selected for membership in ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/10/2017)... CALIF. (PRWEB) , ... October 10, 2017 , ... San ... part of its corporate rebranding initiative announced today. The bold new look is ... reach, as the company moves into a significant growth period. , It will also ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):